Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Mar. 12, 2025 — A lung function test used to help diagnose asthma works better in the morning, becoming less reliable throughout the day, researchers have found. Using real world data from 1,600 ...

Asthma can cause both short-term and long-term complications that can worsen your ability to breathe, perform daily tasks, or get restful sleep. Treatment may help prevent complications from ...